Libertas Bio

Libertas Bio is a clinical-stage biotechnology company focused on developing novel therapies for immunodermatological indications. Libertas Bio's pipeline includes: gusacitinib, an oral Phase 3-ready dual JAK/SYK inhibitor being developed for the treatment of chronic hand eczema; and ASN008, a Phase 2 topical sodium channel blocker being developed for the treatment of atopic dermatitis-associated pruritus.